Pneumoconiosis secondary prevention
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Effective measures for the secondary prevention of pneumoconiosis include avoiding further exposure and being vaccinated. [1]
Secondary Prevention
Effective measures for the secondary prevention of pneumoconiosis include: [2] [3] [4] [5]
- Avoiding further exposure
- Vaccination for influenza
- Vaccination for pneumococcus
- Health surveillance for workers
- Stop smoking
- Treat respiratory infections quickly
References
- ↑ Cullinan P, Reid P (2013). “Pneumoconiosis”. Prim Care Respir J. 22 (2): 249–52. doi:10.4104/pcrj.2013.00055. PMC 6442808. PMID 23708110.
- ↑ Van Dyke MV, Martyny JW, Mroz MM, Silveira LJ, Strand M, Cragle DL; et al. (2011). “Exposure and genetics increase risk of beryllium sensitisation and chronic beryllium disease in the nuclear weapons industry”. Occup Environ Med. 68 (11): 842–8. doi:10.1136/oem.2010.064220. PMC 4347849. PMID 21460389.
- ↑ Sood A (2009). “Current treatment of chronic beryllium disease”. J Occup Environ Hyg. 6 (12): 762–5. doi:10.1080/15459620903158698. PMC 2774897. PMID 19894178.
- ↑ “IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Silica, Some Silicates, Coal Dust and Para-Aramid Fibrils. Lyon, 15-22 October 1996”. IARC Monogr Eval Carcinog Risks Hum. 68: 1–475. 1997. PMC 5366849. PMID 9303953.
- ↑ Pelucchi C, Pira E, Piolatto G, Coggiola M, Carta P, La Vecchia C (2006). “Occupational silica exposure and lung cancer risk: a review of epidemiological studies 1996-2005”. Ann Oncol. 17 (7): 1039–50. doi:10.1093/annonc/mdj125. PMID 16403810.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH